Breaking News on Supplements & Nutrition - EuropeUS edition

Headlines > Regulation

EFSA health claim opinion

Science still matters to Kemin and DSM as EFSA rejects lutein-eye benefits for fourth time

Eyes down! Kemin-DSM lose EU health claim bingo, but say,
Eyes down! Kemin-DSM lose EU health claim bingo, but say, "this opinion changes little for us"

Two years ago lutein player Kemin said it was, “baffled and annoyed”  when EFSA rejected its eye health claim that was already approved in France. This week the EU’s food science agency has done it again, but Kemin and its lutein partner DSM, say they are unperturbed and will, “continue to invest in science”.

After three previous rejections, the article 13.5 proprietary and emerging science submission under the EU nutrition and health claim regulation (NHCR) sought a new angle on the lutein-carotenoid-eye health link – aiming for a “younger and healthier population” as Pedro Vieira, global VP of eye and skin health at Kemin told us this morning.

“What this opinion shows is the ongoing pharma criteria applied to food supplements,” Vieira said.

After previous rejections, the company won’t be bothering with a formal appeal but will send a public letter to the European Commission highlighting its concerns with the opinion.

“But this opinion changes little for us – it would have been nice to have claims for healthier and younger people as the science shows here – but we move on and we will continue to invest in science. That will never change at Kemin.”

The proposed and rejected claim, submitted to EFSA’s Panel on Dietetic Products, Nutrition and Allergies (NDA) in October 2013, was: “Lutein together with zeaxanthin helps maintain clarity and contrast of sight in bright light conditions.”

The dossier’s key study was an unpublished study began in 2009 which showed increases in macular pigment optical density but was discounted by the NDA because of a high drop rate, missing data, a late change in data analysis methods and the fact visual outcome measures were secondary outcomes.

Kemin-DSM provided explanation to NDA questions during a stop-the-clock procedure but the panel's opinion remained unchanged about the study and the overall quality of data.

See the full NDA opinion here .

“we are working on our priorities.”

Vieira said now the NDA opinion was in, the study would be submitted for peer review.

DSM Nutritional Product’s Jens Birrer agreed with Vieira that the opinion was not the end of the world, that the European carotenoid market remained buoyant and that scientific and marketing investment continued around the lutein, zeaxanthin and other ingredients.

He also noted the fact the key study was commissioned in 2009, when the NHCR’s requirements were only just becoming apparent, meant it was more unlikely to drive a successful NDA verdict.

“Definitely guidance is clearer nowadays,” Birrer said. “We are working with Kemin on a new study.”

“But we are working on our priorities. The European market is developing nicely but also it is not the only market.”

Vieira pointed to lutein-eye health approvals in Canada.

Before superseded by the NHCR, lutein had won two approvals from the French Food Safety Agency (ANSES) that stated:

  • “Lutein helps protect the retina and the lens from oxidation”
  • “Lutein is one (of the) constituent(s) of the retina and the lens”

Aside from the 2012 rejection, the NDA rejected lutein dossiers referencing more than 200 studies in 2009 and 2011 and 2012.

Lutein and some other carotenoids are most strongly linked in the scientific literature with reducing the onset of advanced macular degeneration, which tends to affect older people.

The link between lutein and eye health was first reported in 1994 by Dr Johanna Seddon and her co-workers at Harvard University, who found a link between the intake of carotenoid-rich food, particularly dark green leafy vegetables like spinach, and a significant reduction in AMD (JAMA, Vol. 272, pp. 1413-1420).

Subscribe to our FREE newsletter

Get FREE access to authoritative breaking news, videos, podcasts, webinars and white papers. SUBSCRIBE

Post a comment

Comment title *
Your comment *
Your name *
Your email *

We will not publish your email on the site

I agree to Terms and Conditions

These comments have not been moderated. You are encouraged to participate with comments that are relevant to our news stories. You should not post comments that are abusive, threatening, defamatory, misleading or invasive of privacy. For the full terms and conditions for commenting see clause 7 of our Terms and Conditions ‘Participating in Online Communities’. These terms may be updated from time to time, so please read them before posting a comment. Any comment that violates these terms may be removed in its entirety as we do not edit comments. If you wish to complain about a comment please use the "REPORT ABUSE" button or contact the editors.

Related products